Politico August 13, 2024
Erin Schumaker, Toni Odejimi, Daniel Payne and Ruth Reader

INNOVATORS

Don’t count out magic mushrooms.

That’s the message from British biotech company Compass Pathways, which is evaluating ‘shrooms, or psilocybin, alongside psychological support, for treatment-resistant depression.

Approval of the regimen by the FDA could render the agency’s decision last week to reject a different treatment protocol for post-traumatic stress disorder involving the drug MDMA a mere setback in the psychedelic revolution.

The FDA’s decision on MDMA isn’t affecting Compass’ Phase 3 trials, according to Chris Williams, Compass’ chief communications officer.

“Robust monitoring and rigorous standards are at the core of our programs at Compass and we believe that generating clear and compelling clinical evidence is the best way to bring new medicines to patients as quickly as possible,” Williams...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Mental Health, Pharma / Biotech, Provider, Trends
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article